Cytarabine
- Generic Name
- Cytarabine
- Brand Names
- Cytosar, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N3O5
- CAS Number
- 147-94-4
- Unique Ingredient Identifier
- 04079A1RDZ
- Background
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
- Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
Pilot Study of Feasibility of Outpatient Daily High Dose Cytarabine as Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML)
- First Posted Date
- 2014-04-02
- Last Posted Date
- 2018-06-27
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 11
- Registration Number
- NCT02101983
- Locations
- ๐บ๐ธ
University of Rochester, Rochester, New York, United States
Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
- Conditions
- Recurrent B Acute Lymphoblastic Leukemia
- Interventions
- Biological: BlinatumomabProcedure: Allogeneic Hematopoietic Stem Cell TransplantationDrug: CyclophosphamideDrug: AsparaginaseDrug: CytarabineDrug: DexamethasoneDrug: EtoposideDrug: Leucovorin CalciumDrug: MercaptopurineDrug: MethotrexateDrug: PegaspargaseDrug: MitoxantroneDrug: Mitoxantrone HydrochlorideOther: Pharmacological StudyRadiation: Radiation TherapyDrug: Therapeutic HydrocortisoneDrug: ThioguanineDrug: VincristineDrug: Vincristine Sulfate
- First Posted Date
- 2014-04-02
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 669
- Registration Number
- NCT02101853
- Locations
- ๐บ๐ธ
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
๐บ๐ธNYP/Weill Cornell Medical Center, New York, New York, United States
๐บ๐ธState University of New York Upstate Medical University, Syracuse, New York, United States
Selinexor (KPT-330) in Older Patients With Relapsed AML
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2014-03-17
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 317
- Registration Number
- NCT02088541
- Locations
- ๐บ๐ธ
Jonsson Comprehensive Cancer Center / University of California, Los Angeles, Los Angeles, California, United States
๐ณ๐ฑVU University Medical Center, Amsterdam, Netherlands
๐บ๐ธColorado Blood Cancer Institute/Sarah Cannon Research Institute, Denver, Colorado, United States
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic SyndromeAdult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Megakaryoblastic Leukemia (M7)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Pure Erythroid Leukemia (M6b)Secondary Acute Myeloid LeukemiaAdult Acute Myeloblastic Leukemia With Maturation (M2)
- Interventions
- Drug: DaunorubicinDrug: ClofarabineDrug: CytarabineDrug: DecitabineOther: ObservationProcedure: Allogeneic hematopoietic stem cell transplantation
- First Posted Date
- 2014-03-12
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- ECOG-ACRIN Cancer Research Group
- Target Recruit Count
- 727
- Registration Number
- NCT02085408
- Locations
- ๐บ๐ธ
Case Western Reserve University, Cleveland, Ohio, United States
๐บ๐ธBeth Israel Deaconess Medical Center, Boston, Massachusetts, United States
๐บ๐ธNevada Cancer Research Foundation CCOP, Las Vegas, Nevada, United States
Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Refractory Acute Myeloid LeukemiaRecurrent Adult Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2014-02-25
- Last Posted Date
- 2018-12-13
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT02070458
- Locations
- ๐บ๐ธ
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
๐บ๐ธUniversity Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma
- Conditions
- Hodgkin's LymphomaNon-Hodgkin's Lymphoma
- Interventions
- Drug: BendamustineDrug: CarmustineDrug: EtoposideDrug: MelphalanDrug: CytarabineDrug: AlemtuzumabBiological: Autologous Stem Cell TransplantationBiological: Allogeneic Stem Cell TransplantationDrug: Rituximab
- First Posted Date
- 2014-02-11
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 34
- Registration Number
- NCT02059239
- Locations
- ๐บ๐ธ
Weill Cornell Medical College, New York, New York, United States
MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloid Leukemia With Del(5q)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
- Interventions
- Drug: MEK inhibitor MEK162Drug: idarubicinDrug: cytarabineOther: pharmacological studyOther: laboratory biomarker analysis
- First Posted Date
- 2014-01-30
- Last Posted Date
- 2017-12-06
- Lead Sponsor
- Bruno C. Medeiros
- Target Recruit Count
- 1
- Registration Number
- NCT02049801
- Locations
- ๐บ๐ธ
Stanford University, School of Medicine, Stanford, California, United States
Adoptive Transfer of Haplo-identical DLI for AML and MDS
- Conditions
- Acute Myeloid LeukemiaMyelodysplastic Syndrome
- Interventions
- First Posted Date
- 2014-01-27
- Last Posted Date
- 2020-12-03
- Lead Sponsor
- Duke University
- Target Recruit Count
- 19
- Registration Number
- NCT02046122
- Locations
- ๐บ๐ธ
Duke University Medical Center, Durham, North Carolina, United States
Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
- Conditions
- Acute Biphenotypic LeukemiaPreviously Treated Myelodysplastic Syndromede Novo Myelodysplastic SyndromeRecurrent Adult Acute Myeloid LeukemiaUntreated Adult Acute Myeloid LeukemiaSecondary Acute Myeloid Leukemia
- Interventions
- Drug: CladribineDrug: CytarabineBiological: FilgrastimOther: Laboratory Biomarker AnalysisDrug: Mitoxantrone Hydrochloride
- First Posted Date
- 2014-01-24
- Last Posted Date
- 2020-01-10
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 199
- Registration Number
- NCT02044796
- Locations
- ๐บ๐ธ
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Drug: PF-04449913Drug: LDACDrug: Low dose ARA-C (LDAC)Drug: DaunorubicinDrug: AzacitidineDrug: Cytarabine
- First Posted Date
- 2014-01-17
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 48
- Registration Number
- NCT02038777
- Locations
- ๐ฏ๐ต
Japanese Red Cross Nagoya First Hospital, Nagoya, Aichi, Japan
๐ฏ๐ตKobe University Hospital, Kobe-shi, Hyogo, Japan
๐ฏ๐ตAkita University Hospital, Akita, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.